Ministry of Health

Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX

Retrieved on: 
Monday, April 8, 2024
Venus, Magnetic field, Communication, System, Spasm, Abdomen, History, Research, Human, Ministry of Health, Cellulite, Lipolysis, Annual report, Pain, Ministry, FDA

TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.

Key Points: 
  • TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.
  • The Venus Bliss MAX was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance and offered internationally in approved jurisdictions.
  • The Venus Bliss MAX offers three advanced technologies in one platform: diode laser applicators, (MP)2 applicator that combines Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulse™ technology and the Company’s FlexMax EMS applicators.
  • “The Venus Bliss MAX has been well received internationally, and we look forward to bringing our comprehensive all-in-one platform to the Israeli aesthetic service providers,” said Dr. Hemanth Varghese, President and Chief Operating Officer of Venus Concept.

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

Retrieved on: 
Thursday, March 14, 2024
Factitious disorder, Patient, Ministry of Health, Narcotic, Ministry, National Committee, Pharmaceutical industry

HOUSTON, TEXAS, March 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation (Gen-2), 15 milliamp (mA) neurostimulation device into a new mental health center in Oman, dedicated to the use of Nexalin’s neurostimulation device for the treatment of patients with substance abuse disorder (SUD).

Key Points: 
  • HOUSTON, TEXAS, March 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation (Gen-2), 15 milliamp (mA) neurostimulation device into a new mental health center in Oman, dedicated to the use of Nexalin’s neurostimulation device for the treatment of patients with substance abuse disorder (SUD).
  • As previously announced , Nexalin was recently granted regulatory approval for its Gen-2, 15 milliamp (mA) neurostimulation device by the Sultanate of Oman’s Ministry of Health.
  • Mark White, CEO of Nexalin Technology, stated, “We are pleased to commence commercial sales of our Gen-2 neurostimulation device in Oman following regulatory approval by the Sultanate of Oman’s Ministry of Health.
  • Importantly, the new center is exclusively focused on providing comprehensive treatment of patients with SUD, utilizing Nexalin’s Gen-2 neurostimulation device, with plans to expand into the treatment of other mental health disorders.

COVID-19 Monthly Newsletter Service - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Publishing, Health, FDA, COVID-19, Communications, Clinical Trials, MHLW, CSL, Abivax, AstraZeneca, Partnership, University, Ageing, EUL, Arcturus Therapeutics, UNICEF, Bharat Biotech, Ministry of Health, XBB, Messenger, Laboratory, World Health Organization, OTC, Therapy, Johnson & Johnson, Vaccination, Rapid antigen test, Phase II, WHO, CSL Limited, Ministry, Vaccine, Marketing, Fulcrum, UN, Pharmaceutical industry

The "COVID-19 Monthly Snapshot" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Monthly Snapshot" newsletter has been added to ResearchAndMarkets.com's offering.
  • In November 2023, 64 investigational drugs were active in Phase 3 of clinical development.
  • Globally, the overall confirmed cases of COVID-19 reached more than 772 million as of November 22, 2023.
  • Fifty-eight COVID-19 vaccines were evaluated in Phase 3, 40 in Phase 2, 84 in Phase 1, and 199 in pre-clinical stages.

Fiocruz and Caring Cross Announce Collaboration Agreement to Enable Access to Affordable CAR-T Therapy in Brazil and Latin America

Retrieved on: 
Tuesday, March 26, 2024
Organization, HIV, Patient, DSM-IV codes, Knowledge, Ministry of Health, Leukemia, Infection, HIV/AIDS, Ministry, Lymphoma

RIO DE JANEIRO and GAITHERSBURG, Md., March 26, 2024 /PRNewswire/ -- Fundação Oswaldo Cruz (Fiocruz), a foundation from the Brazilian government's Ministry of Health, and Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to advanced medicinal cures for all patients, everywhere, today announced a collaboration to develop local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil, including CAR-T cell therapies for leukemia, lymphoma, and HIV infection.

Key Points: 
  • CAR-T cell therapies represent a revolutionary treatment, harnessing the body's own immune cells to precisely target and destroy infected cells.
  • Caring Cross has developed manufacturing processes that significantly decreases the material cost of manufacturing CAR-T cell therapy products.
  • The agreement with Fiocruz, exclusive to Brazil and Latin America, will not only enable affordable access of CAR-T cell therapies for the Brazilian public health system, but will allow access of critical materials and training needed to manufacture CAR-T cells for other organizations in Brazil and Latin America.
  • "Our collaboration with Fiocruz marks a significant step forward in making CAR-T cell therapies more accessible in Brazil and Latin America," said Boro Dropulić, Ph.D., Executive Director of Caring Cross.

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Retrieved on: 
Thursday, February 29, 2024
DGF, Neonatal Fc receptor, ALS, Congenital myasthenic syndrome, CMS, CIDP, MMN, Alfa Romeo, IIP, IL-6, FDA, Inflammation, MHLW, PDUFA, Euronext, Neurology, MuSK protein, Kidney, ARDA, Health care, C2, GMG, Ministry of Health, Dermatomyositis, Patient, Efgartigimod alfa, MHRA, Medicine, Multifocal motor neuropathy, Immune system, Pharmaceutical industry

“argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • Clinically, we generated significant data through multiple study readouts, achieving key milestones for both the CIDP and MMN patient communities and importantly advancing our second molecule, empasiprubart.
  • Looking forward to 2024, we will act with a continued sense of purpose to expand our patient reach.
  • In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Retrieved on: 
Thursday, March 7, 2024
COVID-19, Research, Infectious Diseases, FDA, Biotechnology, Health, Pharmaceutical, General Health, Science, Pfizer–BioNTech COVID-19 vaccine, Liver, European Commission, Ministry, Arcturus Therapeutics, Messenger, Ornithine transcarbamylase deficiency, Investment, Omicron, OTC, Lyme disease, CSL, MHLW, The Lancet, Vaccine, Gonorrhea, Observation, RNA, Civil service commission, Collaboration, Therapy, COVID, Ministry of Health, Patient, Valence (chemistry), Janssen, Immunity, Orphan, ARCT, Travel, Infection

“I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023,” said Joseph Payne, President & CEO of Arcturus Therapeutics.

Key Points: 
  • “I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023,” said Joseph Payne, President & CEO of Arcturus Therapeutics.
  • This marks the first marketing approval milestone for CSL and Arcturus since signing the Collaboration and License agreement in November 2022.
  • In November 2023, Arcturus received Orphan Drug Designation from the U.S. FDA for ARCT-032, for the treatment of Cystic Fibrosis.
  • We have achieved a total of approximately $396.0 million in upfront payments and milestones from CSL as of December 31, 2023.

American, Finnish and Canadian governments fund oxygen plant at Tatu City SEZ, Kenya

Retrieved on: 
Wednesday, March 6, 2024
Oxygen, George Soros, Davis & Shirtliff, Woman, Ministry, Student, Transport, Pneumonia, Grand Challenges Canada, Pregnancy, Heineken, Ministry of Health, Organization, COVID, CCI, Child, DFC, Mortality, Pharmaceutical industry

TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City Special Economic Zone (SEZ), the 5,000-acre new city on Nairobi's doorstep.

Key Points: 
  • TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City Special Economic Zone (SEZ), the 5,000-acre new city on Nairobi's doorstep.
  • Hewatele will use the debt and equity funds raised to finance the building of a cutting-edge Cryogenic Medical Liquid Oxygen Air Separation Unit plant at Tatu Industrial Park.
  • Dr Bernard Olayo, Founder of Hewatele, said: "This medical oxygen plant represents a significant leap in ensuring sustainable and affordable access to medicinal oxygen.
  • The increased production capacity here at Tatu City will improve oxygen affordability, particularly for maternal and child healthcare, and enhance primary healthcare support."

American, Finnish and Canadian governments fund oxygen plant at Tatu City SEZ, Kenya

Retrieved on: 
Wednesday, March 6, 2024
Oxygen, George Soros, Davis & Shirtliff, Woman, Ministry, Student, Transport, Pneumonia, Grand Challenges Canada, Pregnancy, Heineken, Ministry of Health, Organization, COVID, CCI, Child, DFC, Mortality, Pharmaceutical industry

TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City Special Economic Zone (SEZ), the 5,000-acre new city on Nairobi's doorstep.

Key Points: 
  • TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City Special Economic Zone (SEZ), the 5,000-acre new city on Nairobi's doorstep.
  • Hewatele will use the debt and equity funds raised to finance the building of a cutting-edge Cryogenic Medical Liquid Oxygen Air Separation Unit plant at Tatu Industrial Park.
  • Dr Bernard Olayo, Founder of Hewatele, said: "This medical oxygen plant represents a significant leap in ensuring sustainable and affordable access to medicinal oxygen.
  • The increased production capacity here at Tatu City will improve oxygen affordability, particularly for maternal and child healthcare, and enhance primary healthcare support."

Koning Health Achieves UAE Regulatory Clearance, Paving the Way for Breast CT Commercialization in the Middle East

Retrieved on: 
Wednesday, February 28, 2024
Woman, Ministry, MOH, Female, Growth, Perseverance, Ministry of Health, FANR, MEA, Medical imaging

Maher Bannourah, Director of Koning International, led the initiative by leveraging his industry experience with Ministry of Health (MOH) representatives.

Key Points: 
  • Maher Bannourah, Director of Koning International, led the initiative by leveraging his industry experience with Ministry of Health (MOH) representatives.
  • This regulatory approval positions Koning as the first company to introduce breast CT technology in the UAE, setting a new standard in breast imaging and care in the region.
  • "Koning is honored to be accepted as the only approved breast CT in the UAE.
  • The company is excited to embark on this new chapter of growth and innovation in the UAE and beyond.

Health Affairs Chooses MEI Global to Develop New Partnerships

Retrieved on: 
Tuesday, February 27, 2024
Research, Project, Ministry of Health, Government, Administration, Health Affairs, Health, Health policy, Congress

WASHINGTON, Feb. 27, 2024 /PRNewswire-PRWeb/ -- Today Health Affairs, a journal at the forefront of health policy thought and research, announced it has selected content licensing agency MEI Global, LLC (MEIG) to explore and facilitate new distribution deals. MEIG will help Health Affairs establish third-party licensing partnerships to broaden the reach of Health Affairs' high-level, nonpartisan analysis and research on health policy, as well as how to improve global and domestic health care.

Key Points: 
  • WASHINGTON, Feb. 27, 2024 /PRNewswire-PRWeb/ -- Today Health Affairs , a journal at the forefront of health policy thought and research, announced it has selected content licensing agency MEI Global, LLC (MEIG) to explore and facilitate new distribution deals.
  • MEIG will help Health Affairs establish third-party licensing partnerships to broaden the reach of Health Affairs' high-level, nonpartisan analysis and research on health policy, as well as how to improve global and domestic health care.
  • "With MEIG's guidance...we hope to find partners who can help us reach government and health industry leaders, health care advocates, researchers, and others concerned with health and health care issues around the globe."
  • -- Alan Weil, Health Affairs' Editor-In-Chief
    "We're proud that decision makers at the highest levels, including US Administration officials and members of Congress, ministry of health leaders worldwide, and the US Supreme Court, rely on Health Affairs to ensure they grasp the nuance and depth of the critically important health issues we are facing today," says Alan Weil, Health Affairs' Editor-In-Chief.